

<b>POLICY NAME</b>	Evenity (romosozumab)	<b>POLICY #</b>	2756P
--------------------	-----------------------	-----------------	-------

## Criteria

### Coverage Criteria

- ☐ Documented diagnosis of osteoporosis in a postmenopausal woman
- ☐ Documented T-score below -2.5 OR documentation that the patient is at high risk for bone fracture
- ☐ Documented failure to respond, intolerance, or contraindication to any of the following: OR
  - Two oral bisphosphonates (alendronate, ibandronate)
  - One oral bisphosphonate and IV zoledronic acid (Reclast)
  - One oral bisphosphonate and denosumab (Prolia)
- ☐ Documented severe osteoporosis with continued fracture after one year of continuous bisphosphonate use
- ☐ Patients with severe osteoporosis (T-score  $\leq$  -3 or several vertebral fractures) can bypass trial with bisphosphonates/Prolia based on evidence supporting maximized bone density when receiving Evenity prior to bisphosphonates/Prolia

### Exclusion Criteria – Any of the following prevents coverage

- ☐ Combination therapy involving the use of romosozumab concurrently with another bone mineral density modifying drug
- ☐ Treatment of osteopenia
- ☐ Evenity will not be covered if the member has previously been treated with Forteo or Tymlos